1. North American Center For Limb Preservation Peter Blume, DPM FACFAS Jonathan Key, DPM AACFAS Michael G. Palladino, DPM FACFAS Clinical Research Studies
2. A MULTICENTER, RANDOMIZED, OPEN-LABEL COMPARISON OF THE STUDY AND EFFICACY OF TIGECYCLINE WITH THAT OF AMPICILLIN-SUBLACTAM (UNASYN) OR AMOXICILLIN-CLAVULANATE (AUGMENTIN) TO TREAT COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS. (WYETH, PROTOCOL 3074A1-900 SPONSOR: WYETH PHARMACEUTICALS, INC. Global Medical Affairs PO Box 8299 Philadelphia, PA 19101 CRO: Neddie Zadeikis, MD MBA QUINTILES 445 E. North Water Street #1304 Chicago, IL 60611 312-955-0414
3.
4. LINEZOLID IN THE TREATMENT OF SUBJECTS WITH COMPLICATED SKIN AND SOFT TISSUE INFECTIONS PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS. (PFIZER, ROTOCOL:A5951002) SPONSOR: PFIZER PHARMACEUTICALS New York Headquarters 235 East 42 Street New York, NY 10017 PFIZER CONTACT: Meryl Mendelson, MD 212-733-4923 CRO: COVANCE PERIAPPROVAL SERVICES, INC. One Radnor Corporate Center Radnor, PA 19087 610-687-5454
5. A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRTIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN (PFIZER, PROTOCOL A3191172 ) SPONSOR: PFIZER PHARMACEUTICALS, INC. 235 East 42 nd Street New York, NY 10017-5755 CRO: QUINTILES, INC. 6700 West 115 th Street, 307B Overland Park, KS 66211 CRO CONTACT: Stacy Baker 913-708-6212
6. EFFECT OF DAPTOMYCIN ON HEALING OF ACUTE AND CHRONIC FOOT WOUNDS – AN ANALYSIS OF WOUND FLUIDS (CUBIST, A PILOT STUDY) SPONSOR: CUBIST PHARMACEUTICALS, INC. 65 HAYDEN AVENUE LEXINGTON, MA02421 CUBIST CONTACT: Nayiri Baljian 781-860-8403
7. A PHASE II, DOUBLE-BLINDED, RANDOMIZED, PLACEBO- CONTROLLED STUDY TO ASSESS THE EFFECT OF TOPICAL RECOMBINANT HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR (TELBERMIN) FOR INDUCTION OF HEALING OF DIABETIC FOOT ULCERS (GENENTECH, INC. PROTOCOL VGF3554g) SPONSOR: GENENTECH, INC. 1 DNA Way South San Francisco, CA 94080 MEDICAL MONITOR: Paul Kwon, MD 650-467-8863 CRO: PPD 3151 South 17 th Street Wilmington, NC 28412-6461 PPD PROJECT MANAGER: Jessica Chaparro 910-251-0081
8. A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL, VEHICLE AND STANDARD CARE-CONTROLLED, DOSE-RANGING STUDY ASSESSING THE SAFETY AND EFFICACY OF MRE0094 GEL WHEN APPLIED TOPICALLY FOR 90 DAYS TO SUBJECTS WITH DIABETIC, NEUROTROPHIC, FOOT ULCERS (KING PHARMACEUTICAL RESEARCH AND DEVELOPMENT, INC., PROTOCOL: MRE0094P-201; MRE0094P-202). SPONSOR: KING PHARMACEUTICALS, INC. 4000 CentreGreen Way, Suite 300 Cary, NC 27513 MEDICAL MONITOR: Charles L. Pamplin III, MD 919-653-7042 CRO: RESEARCH POINT 1301 S. Mopac Expressway Suite 50 Austin, TX 78746 CRO CONTACT: Melissa Conroy 512-343-1092
9. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND DOUBLE-DOSE, COMPARATOR ARM (STANDARD OF CARE), MULTICENTER PHASE 2b STUDY OF TOPICAL GAM501 (Ad5PDGF-B/BOVINE TYPE I COLLAGEN GEL) IN THE TREATMENT OF NON-HEALING DIABETIC ULCERS OF THE LOWER EXTREMITY. (TISSUE REPAIR COMPANY) SPONSOR: TISSUE REPAIR COMPANY 11545 Sorrento Valley Road Suite 310 San Diego, CA 92121 CONSULTANT: Symanthis Robertson, MS CCRA 919-789-4536
10. A RANDOMIZED CONTROLLED MULTICENTER TRIAL OF VACUUM ASSISTED CLOSURE (V.A.C.) THERAPY IN THE TREATMENT AND BLINDED EVALUATION OF DIABETIC FOOT ULCERS. (KINETIC CONCEPTS,INC., PROTOCOL:VAC2001-08) SPONSOR: KCI, USA Inc. 8023 Vantage Drive San Antonio, TX 78265 CLINICAL RESEARCH DIRECTOR: Stacey Pugh, RN BSN 210-255-6176 CLINICAL TRIALS COORDINATOR: Kerry Couder 210-255-6660 CLINICAL RESEARCH ASSOCIATE: Rayma Dorris 210-255-6798
11. THE USE OF V.A.C. NEGATIVE PRESSURE WOUND THERAPY (NPWT) ON DIABETIC FOOT AMPUTATION WOUNDS (KINETIC CONCEPTS, INC., PROTOCOL:VAC2006-19) SPONSOR: KCI USA, INC. 8023 Vantage Drive San Antonio, TX 78265 KCI MANAGEMENT MONITOR: Diana Sanchez-Garcia, MBA, RN 800-531-5396 x56661 PRIMARY LEAD INVESTIGATOR: Peter Blume, DPM FACFAS 203-397-0624
12. DETERMINATION OF APPROPRIATE WOUND FLUID COLLECTION AND ANALYSIS METHODS ( KINETIC CONCEPTS, INC., PILOT STUDY, PROTOCOL VACP2006-09) SPONSOR: KCI USA, INC. 8023 Vantage Drive San Antonio, TX 78230 PROJECT MANAGER: Corey Eisenberg 210-255-6713
13. A RANDOMIZED CONTROLLED STUDY COMPARING METABOLITES AND PROTEIN MARKERS IN ACUTE FOOT AMPUTATIONS TREATED WITH V.A.C. THERAPY IN EITHER CONTINUOUS OR INTERMITTANT MODE AND MOIST WOUND THERAPY (KINETIC CONCEPTS, INS.,PROTOCOL: VACP2006-02) SPONSOR: KCI USA, INC. 8023 Vantage Drive San Antonio, TX 78230 KCI MANAGEMENT MONITOR: Katherine Carey, BSN RN 800-531.5396 x56156 PRIMARY LEAD INVESTIGATOR: Peter Blume, DPM FACFAS 203-397-0624
